Supporting data for thesis “Therapeutic Effects of Ganoderma and Its Active Ingredients on Microglial Activation and Polarization in Multiple Sclerosis Treatment”

Supporting data for thesis “Therapeutic Effects of Ganoderma and Its Active Ingredients on Microglial Activation and Polarization in Multiple Sclerosis Treatment”

Multiple Sclerosis (MS), a neurodegenerative disease infecting the central nervous system (CNS), without an effective therapeutic strategy currently. Seeking novel therapeutic strategies for MS is crucial due to its high prevalence and high economic burden. This study investigates the potential of Ganoderma Lucidum Spore Lehuo(GLS) powder, nature product derived from Ganoderma, as a therapeutic agent for MS, with no prior studies examined GLS powder's efficacy in MS treatment. The study used an experimental autoimmune encephalomyelitis (EAE) mouse model to test the hypothesis that GLS could mitigate MS by inhibiting microglial activation and promoting a shift towards an anti-inflammatory M2-like state.The results demonstrated that GLS treatment effectively ameliorated the severity of the disease, and reduced the inflammatory infiltration/demyelination, microglial activation and M2-like polarization in the spinal cord. Meanwhile, GLS could reduce the microglial RNS releasement via suppressing the nuclear factor-κB (NF-κB) signaling pathway in the inflammatory-related BV2 cell model. The in vitro experiments on microglia and neuronal cells also exert protective effects on neurons. Taken together, we conclude that GLS has therapeutic values for treating EAE/MS and decreases the disease severity via attenuating the activation and polarization of microglia to have anti-inflammatory, anti-oxidative effects and inhibiting microglial-derived neuronal death. Further investigation could lead to the development of a promising novel therapeutic agent for Multiple Sclerosis.